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Abstract
Background: There are only few data relating the metabolic consequences of feeding diets very
low in n-3 fatty acids. This experiment carried out in mice aims at studying the impact of dietary n-
3 polyunsaturated fatty acids (PUFA) depletion on hepatic metabolism.
Results: n-3 PUFA depletion leads to a significant decrease in body weight despite a similar caloric
intake or adipose tissue weight. n-3 PUFA depleted mice exhibit hypercholesterolemia (total, HDL,
and LDL cholesterol) as well as an increase in hepatic cholesteryl ester and triglycerides content.
Fatty acid pattern is profoundly modified in hepatic phospholipids and triglycerides. The decrease
in tissue n-3/n-6 PUFA ratio correlates with steatosis. Hepatic mRNA content of key factors
involved in lipid metabolism suggest a decreased lipogenesis (SREBP-1c, FAS, PPARγ), and an
increased β-oxidation (CPT1, PPARα and PGC1α) without modification of fatty acid esterification
(DGAT2, GPAT1), secretion (MTTP) or intracellular transport (L-FABP). Histological analysis
reveals alterations of liver morphology, which can not be explained by inflammatory or oxidative
stress. However, several proteins involved in the unfolded protein response are decreased in
depleted mice.
Conclusion:  n-3 PUFA depletion leads to important metabolic alterations in murine liver.
Steatosis occurs through a mechanism independent of the shift between β-oxidation and
lipogenesis. Moreover, long term n-3 PUFA depletion decreases the expression of factors involved
in the unfolded protein response, suggesting a lower protection against endoplasmic reticulum
stress in hepatocytes upon n-3 PUFA deficiency.
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Background
Dietary n-3 polyunsaturated fatty acids (PUFA) have
important metabolic effects namely through their
involvement in eicosanoid biosynthesis and their ability
to modulate the transcription of regulatory genes [1-4]. n-
3 PUFA are able to coordinate an upregulation of lipid
oxidation and a downregulation of lipid synthesis [5-7].
Through their capacity to function as ligand activators of
peroxisome proliferator-activated receptor α (PPARα), n-
3 PUFA increase fatty acid oxidation [8,9]. On the other
hand, n-3 PUFA suppress lipogenesis by inhibition of
sterol regulatory element binding protein-1c (SREBP-1c)
gene expression and/or proteolytic release [5]. Peroxida-
tion of PUFA has also been proposed as a mechanism
involved in the regulation of lipid metabolism, but this
remains controversial [10-13].
Promoting n-3 PUFA consumption seems to be interest-
ing in the context of reducing metabolic disorders associ-
ated to obesity. Several studies have reported the influence
of n-3 PUFA supplementation on inflammation and lipid
and glucose metabolism [14]. Their results give evidence
of the beneficial effects of these fatty acids on triglyceri-
demia [7], blood pressure [15], inflammation [16,17] and
insulin sensitivity [18,19]. The rationale to propose die-
tary supplementation with n-3 PUFA is also based on the
fact that obese people have a lower level of n-3 PUFA in
plasma [20,21], liver and erythrocyte phospholipids (PL)
[22].
Up till now, it has been rather difficult to assess the patho-
physiological relevance of the modifications of tissue fatty
acid composition due to a lower n-3 PUFA intake. To clar-
ify this point, a rat model with n-3 fatty acids depletion
during two generations has bee developed. Recent data
have shown that these rats display several features of the
metabolic syndrome including visceral obesity [23],
hepatic steatosis [24], insulin resistance [25], cardiac
hypertrophy [26] and perturbation of metabolic, ionic
and functional events in pancreatic islets [25,27]. The bio-
chemical mechanism explaining such metabolic features
remains unclear. The fatty acid pattern is important to
take into account in order to interpret the relevance of die-
tary intervention focused on the physiological role of fatty
acids [28]. We have pointed out that feeding a diet low in
n-3 PUFA profoundly modifies the n-3/n-6 PUFA ratio in
liver tissue. The modification of the hepatic fatty acid
composition also changes the expression of genes consid-
ered as metabolic targets regulated by PUFA in the liver.
We show that n-3 PUFA depletion is associated with
hepatic triglyceride accumulation. Analysis of liver mRNA
content of key factors involved in lipid metabolism dem-
onstrates a decrease in lipogenic gene expression, and an
increase in mRNA coding for enzymes/factors involved in
hepatic catabolism (CPT1, PGC1α). Disturbances of the
mechanism involved in cell protection, namely a decrease
in the unfolded protein response, occur in hepatocytes
upon prolonged n-3 deficiency and may contribute to
hepatic morphological alterations.
Methods
Animals and diets
Control (CT) and second generation n-3 PUFA depleted
(low n-3) female C57Bl/6J mice (Laboratory of Experi-
mental Surgery, Université Libre de Bruxelles, Brussels,
Belgium) were housed in groups of four mice per cage
(twelve per group) at 22°C in an 12 h light/dark cycle and
were given free access to diet and water. The control diet
(AO3, SAFE, Villemoison-sur-orge, France) contained the
following (percent w/w): protein 21, total carbohydrate
52 (including starch 34, cellulose 4), soya oil 5, vitamin
and mineral mixture 5 and water 12. The low n-3 diet con-
tained (percent; w/w) casein 23, corn starch 36, saccha-
rose 26, sunflower oil 5, agar-agar 2, cellulose 2, vitamin
mixture 5 and mineral mixture 1. The n-6/n-3 ratio was
6.1 and 12.4 for the control diet and the low n-3 diet,
respectively. The proportion of the n-3 fatty acids as a per-
centage of total fatty acids was 9% in the control diet and
less than 2% in the low n-3 diet. The relative proportion
of n-6 fatty acids was 55% in the control diet and 22% in
the low n-3 diet. The decrease in total PUFA in the low n-
3 diet was compensated by an increase in the proportion
of monounsaturated fatty acids (MUFA) (+ 17%) and sat-
urated fatty acids (+14%). The major n-3 and n-6 PUFA in
the diets were α-linolenic acid and linoleic acid, respec-
tively. There were only traces of long chain PUFA (EPA,
DHA...) in both control and low n-3 diet. The detailed
fatty acid pattern of these diets was fully described previ-
ously [25].
All mice experiments were approved by the local animal
ethics committee and the housing conditions were as
specified by the Belgian Law of November 14, 1993 on the
protection of laboratory animals (agreement n° LA
1230314).
Food intake assessment
Food intake, taking into account spillage, was recorded
twice weekly during the last three weeks as previously
described [29,30]
Oral glucose tolerance test
An oral glucose tolerance test (gavage with 3 mg glucose/
g body weight; 66% glucose solution) was performed on
6h-fasted mice one week before the end of the treatment.
Blood glucose was determined with a glucose meter
(Roche diagnostic) on 3.5 μl of blood collected from the
tip of the tail vein, 30 min before and 0, 15, 30, 60, 90 and
120 min following glucose injection. Insulin was meas-
ured in 5 μl of plasma samples obtained from tail bloodBMC Physiology 2008, 8:21 http://www.biomedcentral.com/1472-6793/8/21
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at -30 and 15 min using an ELISA kit (Mercodia, Upssala,
Sweden).
Tissue and blood samples
At the age of 34 ± 1 weeks, mice were anaesthetized by
intra-peritoneal injection of sodium pentobarbital solu-
tion (Nembutal®, 60 mg/kg of body weight, Sanofi Santé
Animale, Benelux, Brussels). Vena cava blood samples
were collected in EDTA tubes. After centrifugation (10
min at 1500 g), plasma was stored at -80°C. A fraction of
the main liver lobe was fixed-frozen in isopentane and
kept at -80°C for histological analysis. The excess tissue
material was immediately clamped in liquid N2 and kept
at -80°C. Full and empty caecum, liver, spleen and fat tis-
sues (ovarian, subcutaneous, and visceral) were collected
and weighed.
Liver histological analysis
For the morphological analysis, liver sections were stained
with hematoxylin-eosin. For the detection of neutral lip-
ids, frozen sections were sliced and stained with the oil
red O, using 0.5% oil red O dissolved in propylene glycol
for 10 min at 60°C. The sliced sections were then counter-
stained.
Blood biochemical analysis
Plasma triglycerides (TG), cholesterol (Elitech diagnos-
tics, Sees, France), β-hydroxybutyrate (Stanbio Labora-
tory, Boerne, USA) and non esterified fatty acid (NEFA)
(Wako, Neuss, Germany) concentrations were measured
using kits coupling enzymatic reaction and spectrophoto-
metric detection of reaction end-products. High density
lipoprotein cholesterol (HDL-C) (Diasys Diagnostic and
Systems, Holzheim, Germany) concentration was meas-
ured enzymatically after very low density lipoprotein
(VLDL), chylomicrons and low density lipoprotein cho-
lesterol (LDL-C) antibodies precipitation. LDL was esti-
mated by the Friedwald formula [31]. Cytokines were
determined in 12 μl of plasma using a kit (Bio-Plex Multi-
plex; Bio-Rad, Nazareth, Belgium) and measured using
Luminex technology (Bio-Plex; Bio-Rad).
Tissue biochemical analysis
Fatty acid content was determined in tissue PL and TG as
reported before [32]. For hepatic lipid content measure-
ment, one gram of liver tissue was homogenized in 10 ml
of phosphate buffer (pH 7.4). Lipids were extracted by
mixing 125 μl of homogenate with 1 ml of 2:1 chloro-
form: methanol (Folch et al. 1957). The chloroform phase
was evaporated under nitrogen flux, and the dried residue
was solubilized in 100 μl of isopropanol. TG or choles-
terol were measured as previously described for plasma
samples. Free cholesterol (Diasys Diagnostic and Systems,
Holzheim, Germany) was determined using a kit coupling
enzymatic reaction and spectrophotometric detection of
reaction end-products. Peroxidation was evaluated by
measuring liver thiobarbituric acid-reactive substance
content. Aldehydes contained in tissue homogenates
reacted with thiobarbiuric acid forming an aldehyde-TBA
complex, which can be spectrophotometrically detected
[33]. Hepatic glycogen content was assessed as follows: 20
mg of tissue were dissolved in NaOH 1 M at 55°C for 1 h,
neutralized with HCl 1 M and centrifuged. An aliquot of
the supernatant was incubated in the presence of amy-
loglucosidase (Merck, Darmstadt, Germany) for 2 h at
37°C in a shaking bath. Free glucose was measured as pre-
viously described for plasma samples.
SDS/PAGE and immunoblotting
Approximately 30 mg of frozen liver were homogenized
in RIPA buffer (50 mM HCl, 150 mM NaCl, 1 mM EDTA,
1% NP-40, 0.25% deoxycholic acid, 2 mM sodium
orthovanadate, 5 mM phenylmethylsulfonyl fluoride and
a protease inhibitor cocktail). The homogenates were then
centrifuged for 20 min at 13,000 g. Cell lysates (30 μg)
were combined with Laemmli sample buffer and sepa-
rated by SDS/PAGE. After electrophoretic separation at 40
mA, the proteins were transferred to a PVDF membrane at
80 V for 2 h followed by western blot analysis. Mem-
branes were then incubated in a 5% Blotto solution. Sub-
sequently, membranes were incubated overnight at 4°C
with the following antibodies diluted (1:1000) in TBST
(tris-buffered saline tween-20) containing 1% BSA
(bovine serum albumin): BIP (binding protein), PDI
(protein disulfide isomerase), MBTPS2 (membrane-
bound transcription factor peptidase, site 2), IRE1α
(inositol-requiring enzyme 1 alpha), p-PERK [PKR (dou-
ble-stranded RNA-activated protein kinase R)-like ER
kinase], total PERK, p-JNK (c-jun N-terminal kinase) and
total JNK. All antibodies were purchased from Cell Signal-
ing except total PERK (Abcam, Cambridge, UK). Mem-
branes were washed in TBST and incubated for 1 h at
room temperature in a secondary antibody conjugated to
horseradish peroxidase (1:10,000, Cell Signaling). After
additional washes, chemiluminescence detection was car-
ried out using an Enhanced Chemiluminescent Western
blotting kit (ECL Plus, Amersham Biosciences) and hyper-
films (Hyperfilm ECL, Amersham Biosciences). Then, the
membranes were stripped and re-probed with an anti-
body recognizing GAPDH (Abcam) to which all data were
reported. The films were scanned with an ImageScanner
using the Labscan software and quantified with the Image
Master 1D Image Analysis Software (Amersham Bio-
sciences).
Real-time quantitative PCR
Total RNA was isolated from liver tissue (Roche Diagnos-
tics Belgium, Vilvoorde). cDNA was prepared by reverse
transcription of 1 μg total RNA using the Kit Reverse tran-
scription System (Promega, Leiden, The Netherlands).BMC Physiology 2008, 8:21 http://www.biomedcentral.com/1472-6793/8/21
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Real-time PCRs were performed with the GeneAmp 5700
sequence detection system and software (Applied Biosys-
tems, Den Ijssel, The Netherlands) using SYBER-Green for
detection. RPL19 RNA was chosen as an invariant stand-
ard. Primers and gene details are summarized in table 1.
All tissues were run in duplicate in a single 96-well reac-
tion plate (MicroAmp Optical, Applied Biosystems) and
data were analysed according to the 2-ΔACCT method. The
identity and purity of the amplified product were checked
through analysis of the melting curve carried out at the
end of amplification.
Statistical analysis
Results are presented as mean ± SEM. Statistical signifi-
cance between groups was assessed by Student t-test using
GraphPad Prism version 4.00 for Windows. Pearson's cor-
relation test was used to estimate correlation between two
parameters. P < 0.05 was considered as statistically signif-
icant.
Results
Food intake, body weight and organ weights
Daily energy intake was monitored during the last three
weeks of the experiments. No difference was detected
between CT and low n-3 mice (10.09 ± 0.66 and 9.22 ±
0.05 kcal/cage x day, respectively). Table 2 shows that
body, liver and spleen weights were statistically signifi-
cantly lower in low n-3 mice compared to CT mice. There
was not significant effect of dietary manipulation on vis-
ceral, subcutaneous, and ovarian adipose tissues. Both
caecal tissue and caecal content weights were significantly
reduced by 59% and 56%, respectively, in low n-3 mice.
Parameters related to glucose metabolism (Table 3)
Low n-3 mice exhibited a higher fasting glycaemia com-
pared to CT mice with no effect on fasting insulinemia.
Fifteen minutes after oral glucose loading, plasma insulin
concentrations were strongly increased in low n-3 mice
but their glucose response was similar (AUC mM.min
over 120 min: CT 1851 ± 205, low n-3 1705 ± 130). The
liver glycogen content was higher in low n-3 mice but this
was not statistically significant (p = 0.2). No difference
was detected between CT and low n-3 mice in liver mRNA
coding gluconeogenic key enzymes: phosphoenolpyru-
vate carboxykinase (relative expression, CT = 1.00 ± 0.14,
low n-3 = 1.07 ± 0.16) and glucose 6-phosphatase (rela-
tive expression, CT = 1.00 ± 0.27, low n-3 = 1.31 ± 0.25).
Blood markers of lipid homeostasis
β-OHbutyrate, NEFA and TG levels, measured in the vena
cava, were not modified by the dietary manipulation (β-
OHbutyrate in mM: CT 0.14 ± 0.02, low n-3 0.14 ± 0.02;
NEFA in mM: CT 0.22 ± 0.04, low n-3 0.26 ± 0.04; TG in
mM: CT 0.41 ± 0.04, low n-3 0.34 ± 0.04). However, low
n-3 mice had higher plasma total, HDL, and LDL-choles-
terol concentrations (Figure 1).
Liver fatty acid pattern (Table 4)
The dietary manipulation differently affected the liver
fatty acid pattern in PL and in TG (Table 4). A two-fold
increase in saturated fatty acids (myristic acid C14:0, pal-
mitic acid C:16:0 and arachidic acid C20:0) and monoun-
saturated fatty acids (oleic acid C18:1 n-9 and eicosenoic
acid C20:1 n-9) was observed in liver TG of low n-3 mice.
Only minor changes in saturated fatty acid pattern of the
PL fraction were observed.
Alpha-linolenic acid C18:3 n-3 was undetectable in liver
PL and TG fractions of either CT or low n-3 mice. All long
chain n-3 derivatives were lower in both liver PL and TG
fractions of low n-3 mice. In low n-3 mice docosahexae-
noic acid C22:6 n-3 decreased drastically to reach 15% of
Table 1: Sequences for the primers used in real-time quantitative PCR
GenBank accession no. Forward primer (5' to 3') Reverse primer (5' to 3')
PGC1α NM_008904.1 AGCCGTGACCACTGACAACGAG GCTGCATGGTTCTGAGTGCTAAG
CPT1a NM_013495.1 AGACCGTGAGGAACTCAAACCTAT TGAAGAGTCGCTCCCACT
PPARα NM_011144.3 CAACGGCGTCGAAGACAAA TGACGGTCTCCACGGACAT
PPARγ NM_011146.2 CTGCTCAAGTATGGTGTCCATGA TGAGATGAGGACTCCATCTTTATTCA
FAS NM_007988.3 TTCCAAGACGAAAATGATGC AATTGTGGGATCAGGAGAGC
SREBP-1c NM_011480.2 GATCAAAGAGGAGCCAGTGC TAGATGGTGGCTGCTGAGTG
NOX NM_007807.2 TTGGGTCAGCACTGGCTCTG TGGCGGTGTGCAGTGCTATC
MTTP NM_008642.1 ATGATCCTCTTGGCAGTGCTT TGAGAGGCCAGTTGTGTGAC
DGAT2 NM_026384.3 ACTCTGGAGGTTGGCACCAT GGGTGTGGCTCAGGAGGAT
GPAT1 NM_008149.3 GTCCTGCGCTATCATGTCCA GGATTCCCTGCCTGTGTCTG
G6Pase NM_008061.3 AGGAAGGATGGAGGAAGGAA TGGAACCAGATGGGAAAGAG
PEPCK NM_011044.2 ACCTCCTGGAAGAACAAGGA CTCATGGCTGCTCCTACAAA
L-FABP NM_017399.2 ACCTCATCCAGAAAGGGAAGG ACAATGTCGCCCAATGTCATG
PGC1α; peroxisome proliferator-activated receptor gamma coactivator, CPT1; carnitine palmitoyl transferase 1, PPAR; peroxisome proliferator-
activated receptor, FAS; fatty acid synthase, SREBP-1c; sterol-regulatory-element-binding protein-1c, NOX; NADPH oxidase, MTTP; microsomal 
triglycerides transfert protein, DGAT2; Diacylglycerol acyl transferase 2, GPAT1; Glycerol phosphate acyl transferase 1, G6Pase; glucose 6-
phosphatase, PEPCK; phosphoenolpyruvate carboxykinase, L-FABP; liver fatty acid binding proteinBMC Physiology 2008, 8:21 http://www.biomedcentral.com/1472-6793/8/21
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the control value in liver PL fraction, and 7% of the con-
trol value in liver TG fraction. Eicosapentaenoic acid
C20:5 n-3 was not detectable in liver PL and TG fractions
of low n-3 mice. Arachidonic acid C20:4 n-6 doubled in
liver PL fraction of low n-3 mice compared to CT mice,
whereas linoleic acid C18:2 n-6 content was not modified
in PL. In liver TG fraction of low n-3 animals, there was a
three fold increase in both linoleic and arachidonic acid
levels.
Liver lipid metabolism
Histological analysis of low n-3 mice liver revealed higher
liver macro vesicular TG content (Fig 2). This steatosis was
confirmed by biochemical analysis (TG nmol/mg pro-
teins: CT 97.6 ± 10.0, low n-3 159.0 ± 53.4, p = 0.006).
The amount of TG in liver tissue positively correlated with
the n-6/n-3 ratio in both PL (r2 = 0.97; p = 0.0001) and TG
(r2 = 0.87; p = 0.0007) fractions. A slight increase in total
cholesterol was observed in low n-3 mice (nmol/mg pro-
teins: CT = 37.06 ± 2.56, low n-3 = 42.09 ± 0.81, p =
0,067), which reflected a significant increase in the esteri-
fied fraction (Fig 3). The excess of lipids deposited in the
liver can theoretically result from increased uptake of cir-
culating lipids, from enhanced de novo lipogenesis, from
decreased fatty acid oxidation, or from decreased hepatic
lipoprotein secretion. The key enzymes and nuclear fac-
tors involved in the control of those metabolic pathways
were analysed at the mRNA level. PPARγ is a lipogenic
transcription factor who has already been associated with
steatosis [34]. No modification of its expression occurred
in low n-3 mice. Likewise no change was detected in
SREBP-1c expression, another lipogenic factor under par-
tial control of insulin [35,36,36]. Low n-3 mice exhibited
a lower fatty acid synthase (FAS) expression, the rate-lim-
iting enzyme for fatty acids synthesis (Fig 4). No effect in
low n-3 mice was observed for diacylglycerol acyl trans-
ferase 2 (DGAT2), which is a key enzyme for the esterifi-
cation of diacylglycerol to TG, and on glycerol phosphate
acyl transferase 1 (GPAT1), which is the mitochondrial
enzyme catalysing the first step of fatty acid esterification
to TG and PL. The expression of transcription factors
involved in fatty acid oxidation, namely peroxisome pro-
liferator-activated receptor gamma coactivator α (PGC1α)
and PPARα (p = 0.069), was increased in low n-3 mice.
Carnitine palmitoyl transferase 1 (CPT1), the rate limiting
enzyme for mitochondrial β-oxidation, shows a higher
expression in low n-3 mice compared to CT (p = 0.052)
(Fig 4). These results suggest a lower lipogenic enzyme
activity and a higher hepatic β-oxidation capacity in low
n-3 mice. Liver fatty acid binding protein (L-FABP), which
regulates hepatic fatty acids trafficking, was not modified.
The expression of microsomal triglyceride transfer protein
(MTTP), which drives the association of lipids to apopro-
tein B100 to allow formation of VLDL and further export,
was unchanged (Fig 4).
Liver histological analysis
Histological analysis revealed alterations in hepatic tissue
structure of low n-3 mice. Hepatocytes were shrunk and
nuclei were abnormally dense. No necrotic foci or leuko-
cyte infiltration were observed. Compared to low n-3
mice, stellate cells were more visible in CT mice (Fig 5).
Parameters reflecting cellular stress in liver tissue
Several markers of cellular stress were analysed in liver tis-
sue. Figure 6 shows a paradoxical lower liver lipid perox-
ide content in low n-3 mice compared to CT mice, but no
difference in the expression of NADPH oxidase. Different
Table 2: Body and tissue weight
CT Low n-3
Body weight (g) 22.6 ± 0.7 20.7 ± 0.4*
Liver (g/100 g body wt) 4.50 ± 0.15 3.97 ± 0.08*
Spleen (g/100 g body wt) 0.51 ± 0.06 0.37 ± 0.03*
Pancreas (g/100 g body wt) 0.67 ± 0.04 0.72 ± 0.04
Visceral adipose tissue (g/100 g body wt) 0.66 ± 0.11 0.66 ± 0.02
Ovarian adipose tissue (g/100 g body wt) 0.81 ± 0.14 1.02 ± 0.08
Sub-cutaneous adipose tissue (g/100 g body wt) 1.21 ± 0.16 1.41 ± 0.06
Caecal tissue (g/100 g body wt) 0.58 ± 0.03 0.33 ± 0.02*
Caecal content (g) 0.17 ± 0.01 0.10 ± 0.01*
Data are mean ± SEM. *: means significantly different from the CT group (P < 0.05, Student t-test). n ≥ 8 per group.
Table 3: Glucose metabolism
CT Low n-3
Fasting serum glucose (mmol/l) 5.20 ± 0.29 6.09 ± 0.27*
Fasting serum insulin (pmol/l) 86.2 ± 13.3 92.6 ± 10.8
Post-OGTT serum glucose (mmol/l) 14.5 ± 0.6 16.7 ± 0.9
Post-OGTT serum insulin (pmol/l) 90.4 ± 27.1 217.5 ± 20.2*
Hepatic glycogen content (μg/mg prot) 70.9 ± 15.6 103.7 ± 21.0
OGTT: serum was obtained 15 min after an oral glucose tolerance 
test. Data are mean ± SEM. *: means significantly different from the 
CT group (P < 0.05, Student t-test). n ≥ 8 per group.BMC Physiology 2008, 8:21 http://www.biomedcentral.com/1472-6793/8/21
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cytokines (monocyte chemoattractant protein-1, tumor
necrosis factor α, interleukin 1β, interleukin 6) were
measured in the vena cava but no difference in concentra-
tion was detected between groups (data not shown).
Low n-3 mice exhibited a significant lower hepatic con-
tent of several proteins involved in the unfolded protein
response (UPR): PDI, IRE1α and MBTPS2. Likewise, BIP
was lower in liver of low n-3 mice but the difference did
not reach statistical significance (p = 0.07). No difference
was observed between CT and low n-3 mice for the ratios
of phosphorylated PERK and phosphorylated JNK to their
respective total form (Fig 7).
Discussion
The objective of this study was to investigate the meta-
bolic and toxicologic consequences of n-3 PUFA deple-
tion through a decrease in n-3 PUFA dietary intake for two
generations in mice with a special emphasis on liver tis-
sue. The fatty acid pattern analysis confirmed the n-3
PUFA depletion in hepatic PL and TG fractions of mice fed
for a prolonged period with a diet characterized by low n-
3 PUFA content. Moreover, low n-3 mice exhibited an
increase in saturated, monounsaturated and polyunsatu-
rated n-6 fatty acids mainly in the hepatic TG fraction.
Liver total cholesterol was slightly higher in low n-3 mice,
and this was mainly due to an increased esterified choles-
terol fraction. Cholesterolemia (total, HDL and LDL) was
increased in low n-3 mice. The higher MUFA content in
the liver PL and TG fractions of low n-3 mice could be
responsible for the increased cholesterol esterification. As
a matter of fact, the enzyme involved in cholesterol ester-
ification, acyl-Coenzyme A: cholesterol acyltransferase 2
(ACAT2), preferentially uses MUFA to other fatty acids
[37]. Moreover, previous studies confirm that oleoyl-CoA
and palmitoleyl-CoA liver content, which are increased in
low n-3 mice hepatic TG, are crucial to synthesize esteri-
fied cholesterol [38].
Total TG were significantly higher in liver tissue of low n-
3 mice compared to CT mice. Steatosis was confirmed
both biochemically and histologically in low n-3 mice.
The abnormal accumulation of TG in liver tissue had
already been shown in rats before [24] but, in that rat
model, it was related to an increase in fat mass develop-
ment [23]. Here, low n-3 mice developed hepatic steato-
sis, despite a lower body weight gain and a similar adipose
tissue weight as compared to CT mice, thus suggesting that
steatosis is always present in n-3 deficiency, independent
of fat mass accumulation.
To analyse the biochemical mechanism involved in TG
accumulation, the expression of several factors involved
in lipid metabolism was evaluated in liver tissue of low n-
3 mice as compared to CT mice. Among the factors
involved in the control of hepatic steatosis by PUFA,
PPARα has been considered important[39], even if recent
data are controversial [40]. The liver of low n-3 mice
Cholesterol concentration Figure 1
Cholesterol concentration. (A) Total cholesterol, (B) 
HDL-C and (C) LDL-C were measured in the plasma at the 
end of the experiment. Data are mean ± SEM. *: means signif-
icantly different from the CT group (P < 0.05, Student t-test). 
n ≥ 8 per group.
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showed a higher expression of CPT1, which is compatible
with a higher amount of two cofactors involved in oxida-
tive pathways: PGC1α and PPARα mRNA. Werner et al.
suggested that PPARα activation can be driven by non-
essential LCPUFA, namely the n-9 and n-7 fatty acid fam-
ilies [41]. In fact, we have shown that these fatty acids
were increased in the liver PL and TG fractions of low n-3
mice compared to CT mice, which could lead to PPARα
dependent gene expression.
Low n-3 mice exhibited a lower hepatic expression of FAS,
the rate-limiting enzyme for fatty acid synthesis, whereas
SREBP-1c and PPARγ mRNA levels, considered as drivers
of FAS expression and often associated with tissue TG
accumulation [34,35], were not modified. Insulin is a well
known inducer of fatty acid synthesis, acting through
SREBP-1c activation [35]. In fact, low n-3 mice showed a
higher fasting serum glycaemia compared to CT mice.
This can not be explained through a higher expression of
key gluconeogenic enzymes (phosphoenolpyruvate car-
boxykinase and glucose-6-phosphatase). Moreover, 15
min after a glucose load, low n-3 mice showed a higher
insulin secretion. Therefore, it appears that the liver of low
n-3 animals, despite a higher exposure to glucose and
insulin – reflected by a higher hepatic glycogen content –
directs fatty acids towards catabolic pathways rather than
towards anabolic pathways. This is also supported by the
lack of effect of n-3 PUFA depletion on the expression of
enzymes controlling PL and TG synthesis (GPAT1 and
DGAT2 expression). L-FABP and MTTP involved, respec-
tively, in the intracellular transport of fatty acids and in
the export of TG were not modified by n-3 depletion.
Therefore, the abnormal accumulation of TG in the liver
tissue could be a consequence of hepatic injury rather
than the result of specific metabolic disturbances associ-
ated with n-3 deficiency.
In fact, the histological analysis revealed liver morpholog-
ical alterations in low n-3 mice compared to CT mice. To
explain this hepatic injury, several markers of stress were
measured. No difference was found in the inflammatory
and oxidative stress between CT and low n-3 mice. The
endoplasmic reticulum stress was also evaluated. A recent
study in rats suggests that the composition of fatty acids in
steatotic liver is an important determinant of susceptibil-
ity to liver injury [42]. It was shown that hepatic steatosis
characterized by increased saturated fatty acids leads to
liver injury, endoplasmic reticulum (ER) stress and
impaired regenerative response to liver injury. Moreover,
some models of ER stress show decreased hepatic TG
secretion [43] which may worsen steatosis. ER stress is
caused by the accumulation of unfolded proteins and pro-
Table 4: Fatty acid pattern in liver triglycerides and phospholipids fractions
Triglycerides Phospholipids
(μg/g liver) CT Low n-3 CT Low n-3
C12:0 3.44 ± 3.34 7.88 ± 4.51 ND ND
C14:0 130.7 ± 24.4 242.6 ± 34.3* 22.0 ± 0.9 20.6 ± 0.7
C16:0 4509 ± 360 10320 ± 1054* 4955 ± 77 4718 ± 220
C18:0 395.2 ± 128.1 587.4 ± 76.0 3255 ± 74 3984 ± 203*
C20:0 6.06 ± 3.39 21.7 ± 1.0* 20.9 ± 3.6 17.2 ± 0.5
C22:0 ND ND 70.8 ± 15.5 98.9 ± 5.4*
C24:0 ND ND 90.9 ± 5.9 105.5 ± 2.5
C16:1 n-7 895.2 ± 39.9 1302 ± 201 307.0 ± 20.4 176.9 ± 10.0*
C18:1 n-9 8188 ± 662 16780 ± 2151* 1828 ± 105 1860 ± 146
C20:1 n-9 140.7 ± 17.6 239.4 ± 24.2* 52.6 ± 5.3 39.7 ± 3.9
C18:3 n-3 ND ND ND ND
C20:5 n-3 467.0 ± 9.0 ND 205.4 ± 21.4 ND
C22:3 n-3 ND ND ND ND
C22:5 n-3 87.7 ± 24.4 ND 138.2 ± 7.2 36.0 ± 3.2*
C22:6 n-3 757.5 ± 121.4 50.5 ± 5.1* 4705 ± 132 675.2 ± 48.5*
C18:2 n-6 3540 ± 394 12414 ± 1563* 3644 ± 72 3859 ± 208
C18:3 n-6 58.2 ± 13.9 296.6 ± 64.1* 44.7 ± 4.9 63.0 ± 7.1
C20:2 n-6 41.6 ± 2.4 72.0 ± 5* 86.9 ± 9.6 34.3 ± 10.6*
C20:3 n-6 ND ND ND ND
C20:4 n-6 271.0 ± 40.7 813.6 ± 204.3* 4581 ± 82 7665 ± 228*
C22:4 n-6 55.0 ± 6.4 142.9 ± 41.1 59.3 ± 3.7 169.9 ± 10.0*
Data are mean ± SEM. *: means significantly different from the CT group (P < 0.05, Student t-test). n ≥ 8 per group.BMC Physiology 2008, 8:21 http://www.biomedcentral.com/1472-6793/8/21
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tein aggregates in the ER lumen [44]. To maintain ER
function when the secretory pathway is compromised,
cells have developed an adaptive mechanism called the
unfolded protein response. There are three proximal sen-
sors: PERK, ATF6 and IRE1α. When phosphorylated,
PERK leads to a general decrease of protein translation.
Like IRE1α, ATF6 is involved in the ER chaperone gene
transcriptional induction. IRE1α is also responsible for
the degradation of aggregated protein and the JNK phos-
phorylation. BIP is a chaperone protein and PDI is a fold-
ing catalysts [44,45]. MBTPS2 catalyses the ATF6 cleavage
necessary for its activity [46]. Curiously, western blot anal-
ysis revealed a decrease in most of these proteins involved
in the unfolded protein response (UPR) namely PDI,
MBTPS2, and IRE1α. On the contrary, the hepatic content
of phospho-PERK/PERK and phospho-JNK/JNK was sim-
Fat staining of liver section Figure 2
Fat staining of liver section. (A) CT mice and (B) Low n-3 
mice. Oil red staining was performed on frozen section. Bar 
= 50 μm.
A
B
Liver cholesterol content Figure 3
Liver cholesterol content. CF: free cholesterol; CE: 
esterified cholesterol. Data are mean ± SEM. *: means signifi-
cantly different from the CT group (P < 0.05, Student t-test). 
n ≥ 8 per group.
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Liver gene expression Figure 4
Liver gene expression. The data are presented as a rela-
tive increase (positive value) or decrease (negative value) of 
mRNA liver content measured in low n-3 mice versus CT 
(set at 0 value). See table 1 for primer sequences and abbre-
viations. Data are mean ± SEM. *: means significantly different 
from the CT group (P < 0.05, Student t-test). n ≥ 8 per 
group.
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ilar between low n-3 and CT mice. IRE1α knockout
fibroblasts or mice show no alteration in the transcrip-
tional ER chaperone induction [47,48]. However,
MBTPS2 deletion inhibits ATF6 cleavage and conse-
quently fails to induce BIP [46]. Moreover, MBTPS2 cleav-
age seems also to be necessary for the transcriptional
induction of IRE1α [47]. Therefore, the lower MBTPS2
content may be the key event explaining the decrease in
UPR proteins. These results suggest that long term n-3
PUFA depletion leads to a loss in content of proteins
related to ER stress, which are classically considered as a
mechanism of protection against cell injury. Therefore, we
propose that this mechanism is disturbed by changes in
tissue n-3 PUFA levels, thus could contributing to mor-
phological alterations of liver tissue. The link with steato-
sis remains unclear.
Alternatively, mitochondrial dysfunction is another stress
characterized by hepatic steatosis. It has been shown that
mice deficient in long-chain acyl-CoA dehydrogenase
exhibited higher hepatic lipid storage, increased choleste-
rolemia without any modification in triglyceridemia and
no change in CPT1, PPARα, SREBP-1c, ACC or DGAT2
expression [49]. The similarities in the metabolic pheno-
type of low n-3 mice and mice lacking long-chain-acyl-
CoA dehydrogenase suggest that mitochondrial dysfunc-
tion could be an interesting target to study. Moreover,
there are indications suggesting that n-3 depletion in the
mitochondrial membrane is associated with impaired oxi-
dation [50].
Histological analysis of liver section Figure 5
Histological analysis of liver section. (A) CT mice and 
(B) Low n-3 mice. Hematoxylin and eosin staining; bar = 100 
μm.
A
B
Liver oxidative stress Figure 6
Liver oxidative stress. (A) TBARS (thiobarbituric acid-
reactive substance) content in liver tissue. (B) NOX 
(NADPH oxidase) mRNA level in hepatic tissue. Data are 
mean ± SEM. *: means significantly different from the CT 
group (P < 0.05, Student t-test). n ≥ 8 per group.
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Conclusion
In conclusion, n-3 PUFA depletion in liver tissue pro-
motes steatosis, and leads to alterations in the mecha-
nisms of protection of liver tissue against unfolded
protein induced stress.
The biochemical mechanism involved in TG accumula-
tion remains unknown, and a dynamic study to analyse
VLDL secretion and/or mitochondrial stress by liver tissue
could be interesting perspectives for further studies. Our
results suggest that the lack of dietary n-3 fatty acids –
observed e.g. in obese and diabetic people can be part of
hepatotoxic events linked to steatosis.
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